This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458508091368v1 14/7/981    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sellner, J Articles by Mattle, H P Search for Related Content PubMed PubMed Citation Articles by Sellner, J Articles by Mattle, H P Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATORVASTATIN HEPTANOIC ACID PYRROLE Medline Plus Health Information Statins Social Bookmarking                         What's this?

Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis

¹ Department of Neurology, Inselspital Bern University Hospital, and University of Bern, Bern, Switzerland; Department of Neurology, Klinikum rechts der Isar Technische Universität München, München, Germany
² Department of Neurology, Inselspital Bern University Hospital, and University of Bern, Bern, Switzerland

^* To whom correspondence should be addressed.

	Abstract

The anti-inflammatory potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, as reflected by modulation of C-reactive protein (CRP), might be beneficial in the treatment of patients with multiple sclerosis (MS). We evaluated serum levels of high-sensitivity (hs)-CRP in relapsing–remitting MS patients receiving interferon- 1b and atorvastatin as add-on therapy. This study shows that interferon- treatment is associated with increased serum levels of hs-CRP in MS patients (P < 0.01). In contrast, when atorvastatin is added to interferon-, hs-CRP serum levels decrease to the normal range (P < 0.05), indicating an anti-inflammatory action of atorvastatin in MS. However, whether add-on treatment with atorvastatin modifies the course of MS remains to be investigated.

Key Words: anti-inflammatory, atorvastatin, C-reactive protein, multiple sclerosis

First published on June 23, 2008, doi:10.1177/1352458508091368

Multiple Sclerosis 2008;14:981.

A more recent version of this article appeared on August 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?